These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 6083907)

  • 1. [Significance of disordered antithrombin III function in disseminated intravascular coagulation and deep venous thrombosis for anticoagulant therapy].
    von Blohn G; Reiter B; Hellstern P; Wenzel E; Köhler M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(4):426-38. PubMed ID: 6083907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anti-coagulant therapy--antithrombin III].
    Tsuji H
    Rinsho Ketsueki; 1990 Jun; 31(6):750-5. PubMed ID: 2214165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical aspects of acquired antithrombin III deficiency].
    von Blohn G; Hellstern P; Köhler M; Scheffler P; Wenzel E
    Behring Inst Mitt; 1986 Feb; (79):200-15. PubMed ID: 3718407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of heparin and/or antithrombin III in a model of disseminated intravascular coagulation induced by endotoxin in rabbits].
    Gómez C; Páramo JA; Rocha E
    Sangre (Barc); 1992 Feb; 37(1):5-10. PubMed ID: 1585238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithrombin III substitution in patients in shock].
    Vinazzer H; Blauhut B; Bergmann H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(6):806-16. PubMed ID: 6083957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children.
    Fuse S; Tomita H; Yoshida M; Hori T; Igarashi C; Fujita S
    Am J Hematol; 1996 Sep; 53(1):18-21. PubMed ID: 8813091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of disseminated intravascular coagulation with antithrombin III concentrate in children with verified infection].
    Nowak-Göttl U; Groll A; Kreuz WD; Brand M; Breddin HK; von Loewenich V; Kornhuber B
    Klin Padiatr; 1992; 204(3):134-40. PubMed ID: 1614177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children.
    Hanada T; Abe T; Takita H
    Am J Pediatr Hematol Oncol; 1985; 7(1):3-8. PubMed ID: 4037242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic therapy for deep vein thrombosis.
    Persson AV; Persson CA
    Am J Surg; 1985 Oct; 150(4A):50-3. PubMed ID: 4051121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of recombinant human soluble thrombomodulin (rhs-TM) on a rat model of disseminated intravascular coagulation with decreased levels of plasma antithrombin III.
    Aoki Y; Ohishi R; Takei R; Matsuzaki O; Mohri M; Saitoh K; Gomi K; Sugihara T; Kiyota T; Yamamoto S
    Thromb Haemost; 1994 Apr; 71(4):452-5. PubMed ID: 8052962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology.
    Levi M; Toh CH; Thachil J; Watson HG
    Br J Haematol; 2009 Apr; 145(1):24-33. PubMed ID: 19222477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current views on the therapeutic use of heparin and antithrombin III in disseminated intravascular coagulation].
    Sobczyk J; Swietliński J; Podleśny-Owsińska T
    Pol Tyg Lek; 1989 Oct 2-16; 44(40-42):896-8. PubMed ID: 2487947
    [No Abstract]   [Full Text] [Related]  

  • 13. [Antithrombin III in 86 patients with venous thrombosis (author's transl)].
    Juillet Y; Aiach M; Fiessinger JN; Leclerc M; Housset E
    Sem Hop; 1978 Nov 8-15; 54(37-40):1126-9. PubMed ID: 217091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of hemostatic balance with antithrombin III replacement therapy in a case of liver cirrhosis associated with recurrent venous thrombosis.
    Carmassi F; Morale M; De Negri F; Carrai M
    J Mol Med (Berl); 1995 Feb; 73(2):89-93. PubMed ID: 7627635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current trends in anticoagulant and thrombolytic therapy of thrombosis].
    Gavrilov OK; Rachinskaia NA; Kaveshnikova BF
    Sov Med; 1975 Sep; (9):53-9. PubMed ID: 781864
    [No Abstract]   [Full Text] [Related]  

  • 16. [Antithrombin III activity in relation to multiple administration of various doses of heparin to normal animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Vopr Med Khim; 1985; 31(3):37-41. PubMed ID: 4024529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alteration in coagulation and fibrinolysis after burn injury and significance of anticoagulation therapy using heparin and antithrombin III concentrate].
    Ono I
    Hokkaido Igaku Zasshi; 1987 Jan; 62(1):108-21. PubMed ID: 3817736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrinolytic therapy of deep venous thrombosis. Streptokinase, urokinase, plasminogen substitution].
    Theiss W; Kriessmann A; Wirtzfeld A
    Dtsch Med Wochenschr; 1980 Feb; 105(8):243-6. PubMed ID: 6986252
    [No Abstract]   [Full Text] [Related]  

  • 19. [Possibilities of drug therapy in the fight against deep venous thrombosis].
    Kluken N
    Phlebologie; 1981; 34(3):391-401. PubMed ID: 7291319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III deficiency, deep venous thrombosis, and oral contraceptive use.
    Werner MJ
    J Adolesc Health; 1995 Sep; 17(3):189-92. PubMed ID: 8519788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.